Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoBio, a US-based biopharmaceutical company, has announced a research collaboration deal with Merck's subsidiary to develop vaccine for Respiratory Syncytial Virus (RSV).
Subscribe to our email newsletter
Under the collaboration, the combination of Merck’s proprietary RSV antigen will be evaluated with NanoBio’s NanoStat adjuvant technology, for use as an intranasal vaccine.
As per the deal, Merck can negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.
According to NanoBio, NanoStat-adjuvanted RSV vaccine has demonstrated efficacy in inducing robust protective immunity, without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.